Regarding the m6A-ferroptosis axis, METTL14-modified FGFR4 increases anti-HER2 resistance by inhibiting ferroptosis mediated by the β-catenin/TCF4-SLC7A11/FPN1 axis in recalcitrant HER2-positive breast cancer 113. Here, FGFR4 is linked to breast carcinoma.